Although specific details on ATX-101 combined with immunotherapy are limited, its ability to disrupt PCNA interactions suggests it could potentially enhance the effectiveness of immunotherapeutic agents, providing a rationale for combining ATX-101 with therapies that modulate the immune system to target cancer cells [249]. The gene discussed is PCNA; the disease is cancer.